Education
About Us
Working with TipRanks
Follow Us
Stevanato Group (STVN)
NYSE:STVN
Top Page
Stevanato Group
(NYSE:STVN)
Rating:64Neutral
Price Target:
$25.00
▲(8.65% Upside)
Positive Factors
Financial Performance
Stevanato reported strong second-quarter results, beating both estimates and consensus.
Operational Efficiency
Gross margin and operating margin targets were increased.
Strategic Positioning
Stevanato's facility in Fishers, Indiana, is strategically located next to key customers, enabling supply chain optimization, reduced risk, and increased product integrity.
Negative Factors
Currency and Tariff Challenges
Incremental FX and tariff headwinds prevented a guidance raise.
Engineering Sector Challenges
Messy update from Engineering resulted in reduced guidance due to new project delays.
Profitability Concerns
Management slightly adjusted down its profitability guidance due to the gross impact of tariffs.
Stevanato Group (STVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.28B
Dividend Yield0.26%
Average Volume (3M)380.91K
Price to Earnings (P/E)43.0
Beta (1Y)0.60
Revenue Growth5.95%
EPS Growth7.73%
CountryUS
Employees5,521
SectorHealthcare
Sector Strength51
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.13
Shares Outstanding49,604,650
10 Day Avg. Volume279,310
30 Day Avg. Volume380,910
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue6.15
Enterprise Value/Gross Profit21.94
Enterprise Value/Ebitda24.25
Forecast
1Y Price Target
$28.50Price Target Upside23.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Stevanato Group Business Overview & Revenue Model
Company DescriptionStevanato Group (STVN) is a leading global provider of integrated containment and delivery solutions for the pharmaceutical, biotechnology, and life sciences industries. The company specializes in the design, production, and distribution of glass vials, syringes, cartridges, and other high-quality products essential for drug containment and delivery. Stevanato Group operates across multiple sectors, including healthcare, diagnostics, and industrial applications, providing comprehensive solutions that meet the stringent regulatory standards and safety requirements of the industry.
How the Company Makes MoneyStevanato Group generates revenue primarily through the manufacturing and sale of its proprietary glass and plastic products, which are essential components for the pharmaceutical and biotechnology sectors. The company offers a wide range of solutions, including glass vials, syringes, cartridges, and customized plastic products, which are used for the containment and delivery of drugs. Revenue streams are bolstered by long-term contracts and partnerships with major pharmaceutical companies, which rely on Stevanato’s products for their drug manufacturing and delivery processes. Additionally, the company provides value-added services such as analytical testing and regulatory support, enhancing its revenue potential. Significant factors contributing to its earnings include its advanced manufacturing capabilities, strong intellectual property portfolio, and global distribution network, enabling it to effectively meet the needs of a diverse client base.
Stevanato Group Earnings Call Summary
Earnings Call Date:Aug 05, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:Nov 11, 2025
Earnings Call Sentiment Positive
The earnings call reflected a positive sentiment with strong revenue growth, particularly in high-value solutions, and improvements in profit margins. The company showed resilience in dealing with challenges in the Engineering segment and tariff impacts, and expressed confidence in its long-term growth trajectory.Q1-2025 Updates
Positive Updates
Revenue Growth and Strong Start to Fiscal 2025
The company reported a 9% revenue growth in the first quarter of 2025, reaching EUR 256.6 million, with a strong performance in the Biopharmaceutical and Diagnostics Solutions (BDS) Segment, which grew by 11%.
High-Value Solutions Growth
Revenue from high-value solutions grew 25% to EUR 110.3 million, accounting for 43% of total revenue, driven by strong demand for high-value syringes and stabilization in vial demand.
Improvement in Gross and Operating Profit Margins
Consolidated gross profit margin increased by 80 basis points to 27.2%, and the operating profit margin increased by 280 basis points to 13.5% due to strong performance in the BDS segment and cost-curtailing initiatives.
Positive Order Intake for Vials
Double-digit growth in order intake for both bulk and sterile vials, indicating a recovery in the vial market.
Progress in Capital Investment Projects
Significant progress in the Fishers and Latina facilities, with scaling of commercial syringe production and manufacturing line installations, supporting strong market demand.
Negative Updates
Engineering Segment Challenges
The Engineering segment experienced a 4% revenue decline, primarily due to lower sales from pharmaceutical visual inspection and glass conversion lines, and was impacted by legacy projects in Denmark.
Tariff-Related Impact
An estimated EUR 4.5 million impact on operating profit due to tariffs on goods shipping from the EU to the U.S., with ongoing efforts to mitigate through customer surcharges and supply chain initiatives.
Company Guidance
During the first quarter of fiscal 2025, Stevanato Group reported strong performance, highlighted by a 9% increase in revenue to EUR 256.6 million, driven by an 11% growth in the Biopharmaceutical and Diagnostics Solutions (BDS) segment. High-value solutions, including a modest recovery in EZ-fill vials, accounted for 43% of total revenue. The company's gross profit margin improved by 80 basis points to 27.2%, while operating profit margin rose by 280 basis points to 13.5%. Adjusted EBITDA increased by 100 basis points to 22.4%. Despite a 4% revenue decline in the Engineering segment due to legacy projects in Denmark, the company remains on track to complete these projects in 2025. Looking forward, Stevanato anticipates mid- to high single-digit growth in the BDS segment and neutral to low single-digit growth in the Engineering segment, with continued strong demand for high-value solutions. The company's updated guidance includes anticipated tariff-related impacts of approximately EUR 4.5 million to operating profit, with ongoing mitigation efforts expected to further reduce exposure.Stevanato Group Financial Statement Overview
Summary
Stevanato Group shows strong revenue growth and operational efficiency with stable margins and a solid balance sheet. However, cash flow challenges, particularly negative free cash flow, could pose risks if not addressed. The company should focus on improving cash flow management to support its growth trajectory and maintain financial stability.Income Statement
Stevanato Group shows a solid revenue growth trajectory, with a TTM revenue growth rate of 1.82% and consistent annual growth. The gross profit margin is stable at 28.04% TTM, indicating effective cost management. However, the net profit margin has slightly decreased to 11.75% TTM from previous years, suggesting some pressure on net income. Overall, the company maintains healthy EBIT and EBITDA margins, reflecting operational efficiency.75
Positive
Balance Sheet
The balance sheet is strong with a manageable debt-to-equity ratio of 0.30 TTM, indicating low leverage. Return on equity is moderate at 9.71% TTM, showing decent profitability relative to shareholder equity. The equity ratio stands at a healthy level, suggesting a stable financial structure. However, the slight increase in debt over the years could be a point of concern if it continues.70
Positive
Cash Flow
The cash flow statement reveals challenges, with a negative free cash flow growth rate of -34.96% TTM, indicating cash flow issues. The operating cash flow to net income ratio is 0.43 TTM, showing that operating cash flow covers net income adequately. However, the negative free cash flow to net income ratio suggests that the company is not generating sufficient free cash flow relative to its net income, which could impact future investments.60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.15B | 1.10B | 1.09B | 983.70M | 843.90M | 662.04M |
| Gross Profit | 321.07M | 302.32M | 339.89M | 319.80M | 265.40M | 194.18M |
| EBITDA | 290.47M | 247.80M | 272.35M | 256.40M | 226.93M | 156.38M |
| Net Income | 134.56M | 117.78M | 145.63M | 142.85M | 134.32M | 78.51M |
Balance Sheet | ||||||
| Total Assets | 2.35B | 2.33B | 2.07B | 1.66B | 1.42B | 967.98M |
| Cash, Cash Equivalents and Short-Term Investments | 94.17M | 98.27M | 72.18M | 256.65M | 438.21M | 157.12M |
| Total Debt | 414.95M | 428.97M | 396.59M | 218.37M | 244.29M | 363.01M |
| Total Liabilities | 953.42M | 924.43M | 938.93M | 663.79M | 577.18M | 657.84M |
| Stockholders Equity | 1.40B | 1.40B | 1.13B | 995.90M | 841.70M | 310.50M |
Cash Flow | ||||||
| Free Cash Flow | -64.14M | -157.79M | -336.72M | -139.83M | 20.12M | 59.65M |
| Operating Cash Flow | 206.68M | 155.78M | 105.21M | 103.30M | 133.30M | 155.66M |
| Investing Cash Flow | -268.97M | -310.21M | -421.22M | -243.00M | -96.40M | -96.09M |
| Financing Cash Flow | 81.18M | 183.22M | 158.03M | -44.50M | 254.80M | -26.52M |
Stevanato Group Technical Analysis
Positive
23.01
Price Trends
24.18
Negative
23.37
Negative
22.17
Positive
Market Momentum
-0.46
Negative
48.29
Neutral
69.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STVN, the sentiment is Positive. The current price of 23.01 is above the 20-day moving average (MA) of 22.87, below the 50-day MA of 24.18, and above the 200-day MA of 22.17, indicating a neutral trend. The MACD of -0.46 indicates Negative momentum. The RSI at 48.29 is Neutral, neither overbought nor oversold. The STOCH value of 69.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STVN.
Stevanato Group Risk Analysis
Stevanato Group disclosed 63 risk factors in its most recent earnings report. Stevanato Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stevanato Group Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $5.36B | 46.00 | 8.60% | ― | 10.14% | 0.04% | |
73 Outperform | $5.59B | 29.76 | 4.36% | 1.08% | 1.11% | -23.73% | |
64 Neutral | $6.28B | 42.98 | 9.55% | 0.26% | 5.95% | 7.73% | |
55 Neutral | $5.18B | ― | -4.22% | ― | 8.81% | 40.43% | |
54 Neutral | $6.88B | ― | -0.68% | ― | 8.73% | -245.82% | |
51 Neutral | $7.85B | -0.21 | -41.41% | 2.22% | 22.81% | -2.01% | |
49 Neutral | $3.15B | ― | -1.78% | ― | 2.95% | 47.92% |
* Healthcare Sector Average
Performance Comparison
STVN
Stevanato Group
23.01
1.13
5.16%
ICUI
ICU Medical
127.66
-35.43
-21.72%
MMSI
Merit Medical Systems
90.54
-5.03
-5.26%
RGEN
Repligen
122.32
-19.47
-13.73%
TFX
Teleflex
126.41
-116.06
-47.87%
BLCO
Bausch + Lomb Corporation
14.63
-1.62
-9.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.